FDA approves Otsuka and Lundbeck's long-acting injectable for schizophrenia and bipolar disorder.
TL;DR Summary
The FDA has approved Otsuka and Lundbeck's Abilify Asimtufii (aripiprazole) for the treatment of schizophrenia and as a maintenance therapy for adults with bipolar I. The drug only needs to be injected once every two months, adding to the growing rank of drugs for mental disorders that don't have to be taken as an oral daily treatment.
- FDA approves Otsuka and Lundbeck's schizophrenia, bipolar disorder injection – Endpoints News Endpoints News
- FDA signs off on Otsuka and Lundbeck's longer-acting Abilify FiercePharma
- FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder Pharmacy Times
- NDA Approved for Long-Acting Injectable for Schizophrenia and Bipolar I Psychiatric Times
- FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults Business Wire
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
6 min
vs 7 min read
Condensed
96%
1,325 → 57 words
Want the full story? Read the original article
Read on Endpoints News